Struan is a partner in Bird & Bird’s Corporate Group and is based in the London office. He joined Bird & Bird in May 2010.
Struan's practice focuses on domestic and international corporate transactions for technology companies involving venture capital financings (both equity and debt), mergers and acquisitions and public offerings. His clients include a variety of national and international public and private companies engaged in a wide range of technology sectors including software, semi-conductors, internet, mobile and telecommunications, cleantech and life sciences.
Struan's venture capital practice includes acting for both venture capitalists and investee companies. His client's include Kreos Capital, Arts Alliance, Qio Systems, Phyworks, Imagini and Vegastream. Struan has acted for Imagini on its US$13.5 million second round of funding for its visual profiting business and for Arts Alliance Media in connection with its €23 million fundraising for its digital cinema technology, deployment and content business.
Struan's mergers and acquisitions experience includes acting for CreditCards.com on its acquisition of one of the United Kingdom's leading finance comparison Web sites; Merced Systems on its acquisition of a leading provider of Incentive Compensation Management software; and Analog Devices on its acquisition of a modem software business from TTP Communications plc. Struan also advised GlobalMedia on its acquisition of Bigmouthmedia; QAS Limited and its shareholders on the £106 million disposal to Experian Limited; and Bookham, Inc. (now Oclaro, Inc.) on a number of transactions including the £118 million acquisition of New Focus, Inc. and the reincorporation and listing of Bookham (now Oclaro, Inc.) in the United States via a scheme of arrangement.
On the public offering side, Struan acted for Bookham (now Oclaro, Inc.) and Parthus Technologies plc (now CEVA, Inc.) on their initial public offerings and secondary offerings on the main market of the London Stock Exchange and NASDAQ. Struan also advised ReGen Therapeutics and Blinkx on their flotations on the AIM Market of the London Stock Exchange.
Struan has been recognised as a Top Ranked Lawyer in Venture Capital, The Legal 500 UK in every edition since the 2006. He was also ranked for Private Equity: Venture Capital Investment in Chambers and Partners UK, 2009.